Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction.
Tamoxifen, a non-steroidal anti-estrogen, has been used successfully for a decade as post-operative adjuvant therapy for breast cancer. Tamoxifen is generally well tolerated with few side effects, especially at the typical dose of 10 mg twice daily. However, hepatic effects have been reported after tamoxifen administration and are usually found to be cholestatic in nature. Although previous reports concentrate on tamoxifen as a probable cause of drug-induced hepatotoxicity, very little attention has been focused on the use of tamoxifen in patients with pre-existing liver dysfunction and the possible need for dose adjustment. We present the case of a 48-year-old woman with an acute exacerbation of her pre-existing liver dysfunction and subsequent elevations of tamoxifen blood levels after approximately one year of tamoxifen therapy for adjuvant treatment of breast cancer. Tamoxifen dosing was adjusted based on serum levels.
Floren
L C
LC
Department of Biopharmaceutical Sciences, University of California, San Francisco, USA.
Hebert
M F
MF
Venook
A P
AP
Jordan
V C
VC
Cisneros
A
A
Somberg
K A
KA
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000150:complications*; D008111:Liver Function Tests; D008875:Middle Aged; D013629:Tamoxifen / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen